{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-010993","form_type":"8-K","ticker":"USBC","cik":"0001074828","company_name":"USBC, Inc.","filed_at":"2023-08-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.081517+00:00","generated_at":"2026-06-11T06:46:22.858767+00:00","sec_items":["2.02","2.01","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Know Labs Q3 net loss $3.59M, EPS loss $0.07, cash $3.93M, expects to fund through Dec 2023","bullets":["Net loss of $3.59M in Q3 FY2023 vs $3.03M year ago; EPS loss $0.07 unchanged.","Cash dropped to $3.93M from $12.59M at Sept 30, 2022; net cash used in ops $8.97M in 9 months.","R&D expense rose to $1.87M from $1.27M YoY on Gen1 device development; SG&A fell to $1.35M.","Completed Gen1 non-invasive glucose monitor on June 7, 2023; path to FDA trials and commercialization.","Company expects to raise additional funds via preferred stock, convertible debentures, and equity in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-010993","json":"https://secwatch.observer/filing/0001654954-23-010993.json","markdown":"https://secwatch.observer/filing/0001654954-23-010993.md","text":"https://secwatch.observer/filing/0001654954-23-010993.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1074828/000165495423010993/0001654954-23-010993-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1074828/000165495423010993/know_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T06:46:22.858767+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e2e6d8e5a40032fc684fea6ee74675f2691047f","claim":"USBC, Inc. reported third quarter ended June 30, 2023 results: net income net loss of $3.59 million dollars, EPS loss of $0.07.","evidence_excerpt":"Know Labs reported a net loss of $3.59 million dollars in the third quarter of 2023, compared to a net loss of $3.03 million dollars in the year-ago period, which translates to Earnings Per Share of a loss of $0.07, unchanged from the year ago period of a loss of $0.07 before preferred stock dividends.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1074828/000165495423010993/0001654954-23-010993-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended June 30, 2023"},{"label":"Net income","value":"net loss of $3.59 million dollars"},{"label":"EPS","value":"loss of $0.07"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}